Previous 10 |
Geneva, Switzerland and Boston, MA – August 28, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health...
NEW YORK, Aug. 21, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ObsEva SA (NASDAQ:OBSV), Gran Tierra Energy Inc. (NYSE:GTE), Constellium ...
Obseva SA (OBSV) Q2 2018 Earnings Conference Call August 08, 2018, 08:00 ET Executives Mario Corso - Senior Director, IR Ernest Loumaye - Co-Founder, CEO & Director Timothy Adams - CFO Analysts Martin Auster - Crédit Suisse Kennen MacKay - RBC Capital Markets R...
Geneva, Switzerland and Boston, MA - August 10, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pre...
News, Short Squeeze, Breakout and More Instantly...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 3, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that the Regulatory ...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 18, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that, concurr...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – 28 February 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that it will wind-down its operati...